Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Fernandez De Roitegui Perez (Vitoria Gasteiz, Spain), J. Lobo Beristain (Vitoria Gasteiz, Spain), I. Murga Arizabaleta (Vitoria Gasteiz, Spain), C. Bermudez Ampudia (Vitoria Gasteiz, Spain), A. Maestre (Alicante, Spain), F. Garcia Bragado (Gerona, Spain), R. Otero (Sevilla, Spain), M. Peris (Castellón, Spain), J. Lopez Núlez (Badalona, Spain), P. Verhamme (Leuven, Belgium), M. Monreal (Barcelona, Spain), Riete (Spain, Spain). Sincope is a risk marker in Pulmonary Embolism (PE) with a low risk clinical profile (sPESI:0). 3644

Member's Comments

No comment yet.

Related content which might interest you: Improvements in risk stratification (RS): Beyond the pulmonary embolism severity index (PESI) score Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Relationship between pulmonary embolism severity index (PESI) score and unfavorable inpatient prognosis in non-high risk pulmonary embolism (PE) Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Clinical assessment of pulmonary embolism rule-out criteria (PERC). Retrospective study (2006-2015) Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Pulmonary embolism (PE) in patients with pulmonary sarcoidosis (PS) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Integration of the level of D-dimer (D-d) with Wells criteria to improve the prediction of pulmonary embolism (PE) before CT angiography of the lung (CTAL) Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Role of the PE rule-out criteria (PERC) in patients with suspected pulmonary embolism (PE) in a UK District General Hospital Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Pulmonary artery to aorta ratio and mortality risk in the general population: The Rotterdam study Source: International Congress 2016 – Imaging of COPD and airways: structural and functional assessments Year: 2016 Internal validation of a model to predict the risk of short-term (10 days) adverse outcomes in patients with pulmonary embolism (PE) Source: Annual Congress 2006 - Pulmonary embolism Year: 2006 PERC (Pulmonary Embolism Rule-Out Criteria) puzzle in lung cancer (LC) patients and general population Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019 Results from a national pulmonary embolism (PE) registry: clinical characteristics of 751 acute pe (ape) patients Source: Annual Congress 2009 - Acute and chronic venous thromboembolic disease Year: 2009 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015 The diagnosis of malignancy following a venous thromboembolic event - how high is the risk? Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Clinical characteristics of elderly patients with pulmonary embolism and risk factors for recurrence Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 The management and follow-up of pulmonary embolism (PE) at a district general hospital: Are we missing CTEPH? Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Pulmonary emboli and COVID-19: an increased risk for all? Source: Virtual Congress 2021 – Pulmonary embolism in non-COVID-19 and COVID-19 patients Year: 2021 Difficulties of diagnosis of pulmonary embolism (PE) in patients with lymphangioleiomyomatosis (LAM) Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013 Incidence of pulmonary embolism (PE) in the Pisa area Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006 Incidence of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) at six months of a Pulmonary Embolism (PE). OSIRIS Study Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014